This Article Full Text (PDF) All Versions of this Article: 0003319708321100v1 59/6/695    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by O'Donnell, M. E. Articles by Soong, C. V. Search for Related Content PubMed PubMed Citation Articles by O'Donnell, M. E. Articles by Soong, C. V. Social Bookmarking                         What's this?

The Effects of Cilostazol on Peripheral Neuropathy in Diabetic Patients With Peripheral Arterial Disease

Department of Vascular and Endovascular Surgery, Belfast City Hospital, Belfast, Faculty of Life and Health Sciences, University of Ulster, Ulster Northern Ireland, United Kingdom, modonnell904{at}hotmail.com

Stephen A. Badger, MRCS

Department of Vascular and Endovascular Surgery, Belfast City Hospital, Belfast

Muhammed Anees Sharif, MS, FRCS

Department of Vascular and Endovascular Surgery, Belfast City Hospital, Belfast

Ragai R. Makar, MS, FRCS

Department of Vascular and Endovascular Surgery, Belfast City Hospital, Belfast

Ian S. Young, MD, FRCP, FRCPath

Department of Medicine, Queen's University, Belfast

Bernard Lee, FRCS

Department of Vascular and Endovascular Surgery, Belfast City Hospital, Belfast

Chee V. Soong, MD, FRCS

Department of Vascular and Endovascular Surgery, Belfast City Hospital, Belfast

Background Evidence from diabetic animal models suggests that cilostazol, a cyclic AMP phosphodiesterase inhibitor used in the treatment of claudication, is efficacious in the treatment of peripheral neuropathy, although this is unproven in humans. The main aim of this study was to assess the effects of cilostazol on neuropathic symptomatology in diabetic patients with peripheral arterial disease (PAD). Methods Diabetic patients with PAD were prospectively recruited to a randomized double-blinded placebo-controlled trial. Baseline clinical data were recorded prior to trial commencement following medical optimization. Neurological assessment included the Toronto Clinical Neuropathy Scoring system (TCNS) and vibration perception thresholds (VPT) with a neurothesiometer at baseline, 6 weeks, and 24 weeks. Results Twenty-six patients were recruited from December 2004 to January 2006, which included 20 males. Baseline patient allocation to treatment arms was matched for age, sex, and medical comorbidities. There was no significant difference in neurological assessment between the treatment groups using the TCNS and VPT at 6 and 24 weeks. Conclusions Despite extensive animal-based evidence that cilostazol attenuates neuropathic symptomatology, our results do not support this effect in human diabetic PAD patients.

Key Words: peripheral arterial disease • diabetes • neuropathy • cilostazol

This version was published on January 1, 2009

Angiology, Vol. 59, No. 6, 695-704 (2009)
DOI: 10.1177/0003319708321100


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?